Cetek Corporation

About Cetek • Management • Board of Directors • Scientific Advisory Board • Investors

About Cetek

Cetek Corporation is a biopharmaceutical company engaged in the discovery and early development of novel cancer therapeutics based on the convergent application of its two core technologies: CE Assay™ and the Company's natural-product based drug sources. The broadly applicable CE Assay™ is Cetek's proprietary, high-throughout capillary electrophoresis technology that enables the rapid screening of difficult to assay drug targets as well as conventional targets. Interfacing with CE Assay™ is Cetek's proprietary natural product extract library and its emerging ChemSelect™ library of single-compounds and natural product-like synthetic derivatives. The application of these technologies is driving Cetek’s growing oncology portfolio and creating opportunities for strategic alliances in multiple therapeutic areas. Cetek expects its first proprietary product to enter clinical trials in 2007.

Cetek was founded in 1996. Historically the Company had focused on applying its CE Assay™ technology on a fee-for-service basis, screening targets involved in a wide array of disease indications. Its clients have included, Johnson & Johnson, Schering Plough, Fujisawa and Millennium. More recently Cetek has added a world class natural product drug source, further strengthened its preclinical technologies, and adopted a dual strategy which adds proprietary in-house drug discovery and development.

Cetek has assayed over 8 million compounds since 2001, screening more than 150 validated drug targets. The technology has identified multiple lead compounds for both clients and its own internal discovery initiatives.

Cetek Corporation • 508-229-8900 • info@cetek.com